TSH Biopharm Corp Ltd

TSH Biopharm Corp Ltd maintains a strong liquidity position, with a current ratio of 6.27 and cash and equivalents amounting to 464.54 million TWD. The company's low debt-to-equity ratio of 0.01 indicates a conservative capital structure, with minimal long-term debt exposure. This liquidity profile supports operational flexibility and reduces financial risk. Profitability metrics show a return on equity (ROE) of 9.65% and a return on assets (ROA) of 7.14%, both of which are strong indicators of efficient capital use and asset management. The company's net income of 139.26 million TWD and operating income of 218.37 million TWD reflect solid earnings performance. These figures are in line with industry expectations for a mid-sized pharmaceutical firm. The company's revenue is concentrated in its core pharmaceutical business, with no disclosed geographic diversification. This concentration may expose the company to regional market risks, particularly in the event of regulatory changes or economic downturns in its primary operating region. Looking ahead, TSH Biopharm Corp Ltd is projected to grow revenue to 1.46 billion TWD in the current fiscal year, representing a modest increase from the current 1.34 billion TWD. Analysts expect the company to maintain its earnings momentum, with a mean EPS estimate of 4.03 TWD. The company's capital expenditure of -10.4 million TWD suggests a focus on cost optimization rather than expansion. The company's risk profile is characterized by low liquidity and dilution risks. No immediate filing-based liquidity or dilution flags were detected, and the company's capital structure remains stable. The absence of dilution risk is supported by the fact that basic and diluted shares outstanding are equal, indicating no near-term dilution pressure. Recent filings and transcripts do not indicate any material events that would significantly impact the company's operations or financial health. The company's financial performance and risk profile remain consistent with its historical trends, and there are no signs of distress or strategic shifts in the near term.